Spexis AG
Develops therapeutics for rare diseases, oncology, and antimicrobial resistance.
SPEX | SW
Overview
Corporate Details
- ISIN(s):
- CH0106213793
- LEI:
- 391200S8HJE1I96FIG04
- Country:
- Switzerland
- Address:
- Hegenheimermattweg 125, 4123 Allschwil
- Website:
- https://www.polyphor.com/
- Sector:
- Manufacturing
Description
Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-10-23 19:00 |
Polyphor and the University of Zurich announces publication in 'Nature' of the …
|
English | 7.8 KB | ||
| 2019-09-04 17:38 |
Polyphor to present at the H.C. Wainwright Global Investment Conference
|
English | 7.4 KB | ||
| 2019-09-04 07:00 |
Polyphor announces financial results for the first half 2019 and realigns strat…
|
English | 22.5 KB | ||
| 2019-08-20 17:37 |
Polyphor to host a Key Opinion Leader Meeting in New York on novel approach-es …
|
English | 10.1 KB | ||
| 2019-07-17 07:00 |
Polyphor closes the Phase III PRISM studies of murepavadin intravenous formulat…
|
English | 9.9 KB | ||
| 2019-06-27 07:00 |
Polyphor appoints Frank Weber as new Chief Medical and Development Officer
|
English | 9.4 KB | ||
| 2019-06-20 07:00 |
Polyphor to present its antibiotic programs at the American Society of Microbio…
|
English | 10.7 KB | ||
| 2019-06-19 07:07 |
Polyphor announces enrollment of first patient in FORTRESS Phase III clinical t…
|
English | 12.3 KB | ||
| 2019-06-07 07:00 |
Polyphor presents new in-vivo efficacy and tolerability data for a potential in…
|
English | 12.1 KB | ||
| 2019-05-29 07:00 |
Polyphor and the University of Zurich receive an award from Innosuisse to accel…
|
English | 10.2 KB | ||
| 2019-05-17 07:00 |
Polyphor announces presentation of new survival data on balixafortide at the AS…
|
English | 11.9 KB | ||
| 2019-05-09 18:00 |
Polyphor temporarily halts enrollment in the Phase III studies of murepavadin f…
|
English | 12.6 KB | ||
| 2019-04-17 07:00 |
Polyphor presents new data at ECCMID from its lead antibiotic murepavadin and t…
|
English | 13.0 KB | ||
| 2019-04-16 07:00 |
Polyphor announces enrollment of first patient in PRISM-UDR - the second, FDA a…
|
English | 11.2 KB | ||
| 2019-04-12 17:45 |
Polyphor shareholders approve all motions proposed by the Board of Directors at…
|
English | 7.8 KB |
Automate Your Workflow. Get a real-time feed of all Spexis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Spexis AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Spexis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-21 | N/A | Executive member | Other | None | N/A |
Peer Companies
